231
Participants
Start Date
February 7, 2012
Primary Completion Date
November 26, 2018
Study Completion Date
November 26, 2018
natalizumab
Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
Research Site, New York
Research Site, New York
Research Site, Staten Island
Research Site, Patchogue
Research Site, Stony Brook
Research Site, Plainview
Research Site, Newark
Research Site, Washington D.C.
Research Site, Baltimore
Research Site, Norfolk
Research Site, Newport News
Research Site, Atlanta
Research Site, Jacksonville
Research Site, Homewood
Research Site, Louisville
Research Site, Gahanna
Research Site, Cleveland
Research Site, Uniontown
Research Site, Cincinnati
Research Site, Indianapolis
Research Site, Indianapolis
Research Site, East Lansing
Research Site, Lake Barrington
Research Site, Chicago
Research Site, Peoria
Research Site, Overland Park
Research Site, Lincoln
Research Site, New Orleans
Research Site, Dallas
Research Site, Round Rock
Research Site, Aurora
Research Site, Fort Collins
Research Site, Salt Lake City
Research Site, Sun City
Research Site, Los Angeles
Research Site, La Jolla
Research Site, Portland
Research Site, Seattle
Research Site, Tacoma
Research Site, Boston
Research Site, Lexington
Research Site, Wellesley Hills
Research Site, Worcester
Research Site, Freehold
Lead Sponsor
Biogen
INDUSTRY